SurModics (SRDX) Tops Q2 EPS by 12c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Surmodics Reports Second Quarter Fiscal 2022 Results
April 27, 2022 7:30 AM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022.
Summary of Second Quarter and Recent Highlights
Revenue of $26.1 million, a sequential increase of 13% Record In Vitro Diagnostics revenue of $7.7 million GAAP EPS of $(0.29), non-GAAP EPS of $(0.22) Double-digit product sales growth year-over-year from both Medical Device and In Vitro... More